Physician profile
Charles K Phillips
NPI 1821089905
$8,777.98
in general payments reported to CMS, 2019-2025
57 companies · $887 in 2025
The $887 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,825 · 2020: $1,993 · 2021: $2,416 · 2022: $302 · 2023: $112 · 2024: $1,243 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.28 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $884.24 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $774.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $741.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $624.06 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $504.61 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $469.22 | 2019-2025 | |
| Amgen INC. | $430.50 | 2019-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.11 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $366.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.57 | 2019-2022 | |
| Amarin Pharma, INC. | $333.13 | 2019-2021 | |
| Allergan, INC. | $237.61 | 2019-2020 | |
| Abbott Laboratories | $210.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $186.18 | 2019-2025 | Capvaxive, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $168.32 | 2020-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.